Financing round of 17 MDKK
Proceeds will allow expansion and acceleration of the company’s ongoing clinical registration study in migraine with aura
Combined with Rehaler’s recent EU grant of 11 MDKK, this funding ensures adequate capital to complete the registration trial, expand team and file for FDA clearance and CE certification
Rehaler, a private medical technology company focusing on an innovative treatment
solution for migraine with aura, today announced the successful closing of a finance
round totalling 17 MDKK.
“We are very pleased with having received the confidence of several knowledgeable and
experienced private investors, in addition to a significant investment level from existing
shareholders. This financing will be used for maturing the company and accelerating our
pivotal clinical registration study for our novel device which represents a new treatment
option for patients with migraine with aura. The objective is to obtain registration in the U.S.
and create data supporting the commercialization of the device in both the U.S. and EU,
starting in 2025”, says Henrik Olsen, Chief Executive Officer.
“Rehaler’s technology and mechanisms of action offer significant medical and commercial
opportunities within the headache field and in a number of other neurological disorders. The
combination of a late-stage asset within the migraine field and a platform which may be utilized in other indications provides the opportunity to create significant value and develop a
highly successful medical technology company”, says Thomas Feldthus, Chairman of the
Board at Rehaler A/S.
“The patented CO2 modulation concept of the Rehaler device is supported by good
clinical feasibility data. Rehaler has its own production line which means that we are ready
to commercialize the product following the completion of the clinical trial that will enable
market clearance in the US”, says Troels Johansen, CTO and co-founder.
Contact:
Henrik Olsen, CEO
Tel: +45 5387 3380
Email: ho@rehaler.com
Rehaler is a private medical technology company developing and commercializing novel treatments based on modulation of CO2 and oxygen in the central nervous system. Rehaler has obtained proof-of-concept for its first product, the Rehaler device for treatment of migraine with aura. Rehaler is currently running a pivotal clinical registration study, which was initiated in August 2023 with the aim of obtaining market approval in the U.S. and support commercialization in the U.S. and Europe. The company’s technology platform has applications in several other neurological disorders which will be investigated alongside the registration study. Read more at www.rehaler.com.
